कृपया अन्य खोज का प्रयास करें
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
David G. Elsley | - | 2017 | President, CEO & Director |
Guillermo Torre-Amione | - | 2018 | Independent Chairman |
Peter Pekos | - | 2017 | Independent Director |
Christopher J. Waddick | - | 2018 | CFO, Corporate Secretary & Director |
Colin G. Stott | 58 | 2019 | Independent Director |
Bruce McManus | - | 2022 | Member of Scientific Advisory Board |
Paul M. Ridker | - | 2022 | Member of Scientific Advisory Board |
Michael Jay Willner | 66 | 2021 | Independent Director |
Joseph A. Hill | - | 2022 | Member of Scientific Advisory Board |
Teri Loxam | 51 | 2022 | Independent Director |
Jennifer M. Chao | 54 | 2022 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है